NTLA vs QDEL: stock comparison and AI forecast
Intellia Therapeutics, Inc. (NTLA) and Quidelortho Corp (QDEL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NTLA Intellia Therapeutics, Inc.
- Market Cap
- $1.75B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
QDEL Quidelortho Corp
- Market Cap
- $966M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- NTLA is 1.8 times larger than QDEL by market capitalization ($1.75B against $966M).
- QDEL turns -39.2% of its revenue into net income, against -672.2% for NTLA.
- QDEL carries 2.22 times debt per unit of equity, against 0.18 times for NTLA.
- Both companies share the SEC industry classification In Vitro & In Vivo Diagnostic Substances.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NTLA | QDEL |
|---|---|---|
| Market Cap | $1.75B | $966M |
| P/B Ratio | 2.40x | 0.54x |
| EPS | $-2.53 | $-15.44 |
| Book Value/Share | $5.19 | $25.88 |
| Revenue/Share | $0.42 | $39.00 |
| FCF/Share | $-2.49 | $-4.19 |
Profitability & Margins
| Metric | NTLA | QDEL |
|---|---|---|
| ROE | -55.0% | -59.1% |
| ROA | -46.7% | -18.3% |
| ROIC | -54.5% | -17.5% |
| Gross Margin | – | 44.6% |
| Operating Margin | -711.7% | -30.8% |
| Net Margin | -672.2% | -39.2% |
| EBT Margin | -711.7% | -38.5% |
| Tax Rate | – | -1.8% |
Financial Health
| Metric | NTLA | QDEL |
|---|---|---|
| Current Ratio | 6.65x | 1.39x |
| Quick Ratio | – | 0.76x |
| D/E Ratio | 0.18x | 2.22x |
| Financial Leverage | 1.18x | 3.22x |
| Interest Coverage | – | -0.4x |
| Working Capital | $448M | $383M |
Cash Flow
| Metric | NTLA | QDEL |
|---|---|---|
| Operating Cash Flow | -$347M | -$156M |
| Free Cash Flow | -$349M | -$288M |
| Capital Spending | -$2M | -$132M |
| OCF Growth YoY | – | -158.4% |
| FCF Growth YoY | – | -422.4% |
| FCF/Sales | -586.0% | -10.8% |
| CapEx/Sales | 3.4% | 4.9% |
Operational Efficiency
| Metric | NTLA | QDEL |
|---|---|---|
| Asset Turnover | 0.07x | 0.47x |
| Receivables Turnover | 8.1x | 7.6x |
| Inventory Turnover | – | 2.4x |
| Fixed Assets Turnover | 4.0x | 2.0x |
| Days Sales Outstanding | 45 days | 48 days |
| Days Inventory | – | 152 days |
| Payables Period | – | 58 days |
| Cash Conversion Cycle | – | 142 days |
Income Statement
| Metric | NTLA | QDEL |
|---|---|---|
| Total Revenue | $60M | $2.67B |
| Operating Income | -$423M | -$825M |
| Net Income | -$400M | -$1.05B |
| R&D Expense | $347M | $181M |
| SG&A Expense | – | $770M |
| Cost of Goods Sold | – | $1.48B |
Dividend & Shareholder Information
| Metric | NTLA | QDEL |
|---|---|---|
| Shares Outstanding | 140M | 69M |
NTLA vs QDEL: stock comparison and AI forecast
Which is bigger, NTLA or QDEL?
NTLA is 1.8 times larger than QDEL by market capitalization ($1.75B against $966M).
Which one does Intratio's AI model rank higher, NTLA or QDEL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.